13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00623415
(ClinicalTrials.gov)
December 200715/2/2008Flupirtine as Oral Treatment in Multiple SclerosisMulticentric, Prospective, Double Blind, Randomized/Stratified, Placebo-controlled Pilot-study for Evaluation of Safety and Efficacy of Flupirtine add-on to Interferon-ß1b on Neurodegeneration in Patients With Relapsing Remitting Multiple SclerosisRelapsing Remitting Multiple SclerosisDrug: Flupirtine;Drug: PlaceboCharite University, Berlin, GermanyBayerTerminated18 Years60 YearsAll30Phase 2Germany
2EUCTR2006-005262-39-DE
(EUCTR)
30/05/200709/03/2007Flupirtin as Oral Treatment in MS - FLORIMSFlupirtin as Oral Treatment in MS - FLORIMS Relapsing-remitting multiple sclerosisTrade Name: Trancopal Dolo
Product Name: Flupirtin
INN or Proposed INN: Flupirtin
Other descriptive name: Flupirtinmaleat
Charité-Universitätsmedizin BerlinNULLNot RecruitingFemale: yes
Male: yes
Germany